跳至主要内容
临床试验/NCT05129202
NCT05129202已完成不适用

Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases:A Retrospective Study

Hunan Province Tumor Hospital1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2017年11月3日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
200
试验地点
1
主要终点
PFS

研究概览

简要总结

Non-small cell lung cancer patients may have brain metastases at diagnosis. Patients with brain metastasis may contribute as poor prognosis factors. This trial aims to explore the efficacy and the safety of immune checkpoint inhibitors in non small cell lung cancer patients with initial brain metastasis.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 1.Diagnosed with advanced non-small cell lung cancer 2.Patients with brain metastasis
  • Treated with ICIs

排除标准

  • 1.Patients with a clear driver mutation that can be targeted for first-line treatment

研究组 & 干预措施

immuntherapy

patients treated with immune checkpoint inhibitor monotherapy or combination therapy.

干预措施: immune therapy (Drug)

结局指标

主要结局

PFS

时间窗: November 2017- October 2021

progression free survival

ORR

时间窗: November 2017- October 2021

disease remission rate

次要结局

  • OS(November 2017- October 2021)

研究者

发起方
Hunan Province Tumor Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Yongchang Zhang

Director, Head of Medical Oncology, Principal Investigator, Clinical Professor

Hunan Province Tumor Hospital

研究点 (1)

Loading locations...

相似试验